Myoblast differentiation promoter

Abstract

A peptide selected from the group consisting of Ala-Hyp-Gly, Hyp-Gly-Pro, Leu-Hyp, Glu-Hyp, Gly-Pro-Hyp, Pro-Ala, Hyp-Gly and Pro-Hyp, or a pharmaceutically acceptable salt thereof has a myoblast differentiation promoting effect superior to conventional arts.

1 . A method for promoting myoblast differentiation promoter comprising administering a peptide selected from the group consisting of Ala-Hyp-Gly, Hyp-Gly-Pro, Leu-Hyp, Glu-Hyp, Gly-Pro-Hyp, Pro-Ala, Hyp-Gly and Pro-Hyp, or a pharmaceutically acceptable salt thereof, to a subject in need thereof. 
     
     
         2 . The method according to  claim 1 , comprising administering a peptide selected from the group consisting of Hyp-Gly and Pro-Hyp, or a pharmaceutically acceptable salt thereof, to a subject in need thereof. 
     
     
         3 . The method according to  claim 1 , comprising administering two or more peptides selected from the group consisting of Ala-Hyp-Gly, Hyp-Gly-Pro, Leu-Hyp, Glu-Hyp, Gly-Pro-Hyp, Pro-Ala, Hyp-Gly and Pro-Hyp, or pharmaceutically acceptable salts thereof, to a subject in need thereof. 
     
     
         4 . The method according to  claim 1 , wherein the peptide(s) are administered in the form of a preparation for oral administration, an injection for direct administration to muscle, a transdermal agent, a suppository, a nasal drop, or an inhalant. 
     
     
         5 . A beverage or food product or a feed, comprising a peptide selected from the group consisting of Ala-Hyp-Gly, Hyp-Gly-Pro, Leu-Hyp, Glu-Hyp, Gly-Pro-Hyp, Pro-Ala, Hyp-Gly and Pro-Hyp, or a pharmaceutically acceptable salt thereof 
     
     
         6 . The method according to  claim 1 , used for therapy of locomotive syndrome, therapy of sarcopenia, improvement in the effect of training in athletes, students and so on, enhancement in physical strength of aged persons, long-stay inpatients and so on, and improvement in quality of meat of livestock. 
     
     
         7 . The method according to  claim 1 , wherein the dose of the peptide(s) per day for one adult is about 1 to 1000 mg in the case of oral administration, and about 0.01 to 200 mg in the case of direct administration to a diseased part. 
     
     
         8 . The method according to  claim 1 , wherein the peptide(s) is administered with other active ingredient(s) and/or ingredient(s) for formulation.